Evotec SE (NASDAQ:EVO - Free Report) - Equities researchers at HC Wainwright increased their Q2 2025 earnings estimates for shares of Evotec in a report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.06). The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.02 EPS and FY2027 earnings at $0.44 EPS.
Separately, Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.
Check Out Our Latest Stock Analysis on Evotec
Evotec Stock Performance
Shares of NASDAQ EVO traded up $0.11 during mid-day trading on Monday, hitting $4.05. 19,144 shares of the company's stock traded hands, compared to its average volume of 131,413. The company's 50-day moving average is $3.65 and its two-hundred day moving average is $4.17. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. Evotec has a 1 year low of $2.84 and a 1 year high of $5.64.
Hedge Funds Weigh In On Evotec
A number of hedge funds have recently added to or reduced their stakes in EVO. DCF Advisers LLC grew its stake in Evotec by 227.0% in the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after acquiring an additional 521,708 shares in the last quarter. ABC Arbitrage SA bought a new position in shares of Evotec during the first quarter valued at approximately $260,000. Lighthouse Investment Partners LLC bought a new position in shares of Evotec during the fourth quarter valued at approximately $166,000. CSS LLC IL bought a new position in shares of Evotec during the fourth quarter valued at approximately $50,000. Finally, Bank of America Corp DE boosted its stake in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. 5.81% of the stock is currently owned by institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
